Abstract
Dupilumab, a fully human mAb, blocks the shared receptor component for interleukin-4/interleukin-13. Part A of a 3-part, phase 3 study (NCT03633617) evaluated the efficacy/safety of weekly dupilumab 300mg versus placebo in adolescent/adult EoE patients. Co-primary endpoints, proportion of patients achieving peak esophageal intraepithelial eosinophil count ≤6eos/hpf, and change from baseline in Dysphagia Symptom Questionnaire score at Week 24, were achieved and dupilumab was well tolerated. This analysis assesses dupilumab’s effect versus placebo on HRQoL and symptom burden at Week 24 (secondary/exploratory endpoints).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
